Rihs José Bryan, Vilela Mariana Teixeira, Dos Santos Janete Soares Coelho, de Souza Filho Job Alves, Caldas Sérgio, Leite Rodrigo Souza, Mol Marcos Paulo Gomes
Ezequiel Dias Foundation, Directorate of Research and Development, Belo Horizonte, Minas Gerais, 30510-010, Brazil.
Acta Parasitol. 2025 Jan 7;70(1):16. doi: 10.1007/s11686-024-00942-8.
Ensuring accuracy in the diagnosis of leishmaniasis is crucial due to the myriad of potential differential diagnoses. Given the inherent limitations of serological techniques, real-time polymerase chain reaction (qPCR) emerges as a superior alternative. Furthermore, parasitological methods, conventionally regarded as the gold standard owing to their high specificity, encounter challenges concerning sensitivity and invasiveness for patients. In this context, the present study aims to assess, via meta-analysis, the performance of qPCR in diagnosing visceral and cutaneous leishmaniasis.
This meta-analysis encompassed studies published between January 2011 and December 2022, sourced from six databases (PubMed, LILACS, Scopus, Scielo, EMBASE, and Web of Science), utilizing the keywords "qPCR," "molecular diagnosis," and "leishmaniasis." Epidemiological studies focusing on the efficacy of qPCR for leishmaniasis diagnosis were included. Data such as study demographics, geographic locations, sampling techniques, and the number of positive qPCR results were aggregated and analyzed to derive overall positivity rates, sensitivity, and specificity values associated with qPCR. Heterogeneity analysis was conducted on the data to select appropriate models, and the collective efficacy data of qPCR were illustrated in forest plots.
Fifty-four studies met all inclusion criteria. The positivity rates for human visceral and cutaneous leishmaniasis were 27.07% (95% CI: 17.81-36.33%) and 60.40% (95% CI: 30.23-90.57%), respectively. In cases of visceral leishmaniasis in dogs, cats, and wild animals, the positivity rates were 26.55% (95% CI: 21.40-31.70%), 0.92% (95% CI: 0.09-1.75%), and 28.98% (95% CI: 21.86-35.10%), respectively. Analysis of the selected studies revealed high overall sensitivity and specificity values achieved with qPCR, at 91.08% (95% CI: 81.77-100.39%) and 98.08% (95% CI: 97.13-99.03%), respectively.
This study indicates that qPCR is a highly sensitive and specific tool, adequately suitable for the diagnosis of human visceral and cutaneous leishmaniasis, as well as visceral leishmaniasis in animals.
由于存在众多潜在的鉴别诊断,确保利什曼病诊断的准确性至关重要。鉴于血清学技术的固有局限性,实时聚合酶链反应(qPCR)成为一种更优的替代方法。此外,寄生虫学方法虽因其高特异性传统上被视为金标准,但在敏感性和对患者的侵入性方面存在挑战。在此背景下,本研究旨在通过荟萃分析评估qPCR在诊断内脏利什曼病和皮肤利什曼病方面的性能。
本荟萃分析纳入了2011年1月至2022年12月期间发表的研究,这些研究来自六个数据库(PubMed、LILACS、Scopus、Scielo、EMBASE和Web of Science),使用了关键词“qPCR”、“分子诊断”和“利什曼病”。纳入了关注qPCR诊断利什曼病疗效的流行病学研究。汇总并分析了研究人口统计学、地理位置、采样技术和qPCR阳性结果数量等数据,以得出与qPCR相关的总体阳性率、敏感性和特异性值。对数据进行异质性分析以选择合适的模型,并在森林图中展示qPCR的综合疗效数据。
54项研究符合所有纳入标准。人类内脏利什曼病和皮肤利什曼病的阳性率分别为27.07%(95%CI:17.81 - 36.33%)和60.40%(95%CI:30.23 - 90.57%)。在犬、猫和野生动物的内脏利什曼病病例中,阳性率分别为26.55%(95%CI:21.40 - 31.70%)、0.92%(95%CI:0.09 - 1.75%)和28.98%(95%CI:21.86 - 35.10%)。对所选研究的分析显示,qPCR具有较高的总体敏感性和特异性值,分别为91.08%(95%CI:81.77 - 100.39%)和98.08%(95%CI:97.13 - 99.03%)。
本研究表明,qPCR是一种高度敏感和特异的工具,足以适用于诊断人类内脏利什曼病和皮肤利什曼病以及动物的内脏利什曼病。